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Purpose: To determine the long-term impact of stereotactic radiotherapy (SRT) on the quality of life (QoL) of inoperable
patients with early-stage non-small cell lung cancer (NSCLC).
Methods and materials: From January 2006 to February 2008, 39 patients with pathologically confirmed T1-2N0M0
NSCLC were treated with SRT. QoL, overall survival and local tumor control were assessed. The European Organization
for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ)-C30 and the lung cancer-specific
questionnaire QLQ-LC13 were used to investigate changes in QoL. Assessments were done before treatment, at 3 weeks,
every 2–3 months during the first two years, and then every 6 months until 5 years after the treatment or death or
progressive disease. The median follow up was 38 months.
Results: During the 5 years after treatment with SRT for stage I NSCLC, the level of QoL was maintained: There was
a slow decline (slope: −0.015) of the global health status over the 5 years (p < 0.0001). The physical functioning and the
role functioning improved slowly (slope: 0.006 and 0.004, resp.) over the years and this was also significant (p < 0.0001).
The emotional functioning (EF) improved significantly at 1 year compared to the baseline. Two years after the treatment
dyspnea slowly increased (slope: 0.005, p = 0.006). The actuarial overall survival was 62% at 2 years and 31% at 5-years.
Conclusion: QoL was maintained 5 years after SRT for stage I NSCLC and EF improved significantly. Dyspnea slowly
increased 2 years after the treatment.Background
Stereotactic radiotherapy (SRT) has proved to be a good
alternative treatment to surgery for medically inoperable
patients with early stage non-small cell lung cancer
(NSCLC). Prospective trials evaluating the use of SRT
showed excellent local tumor control rates (78%–97%)
[1]. Overall survival, while more variable, has improved
compared to historical controls [1,2]. The treatment is
well tolerated, even in elderly patients [3,4]. An essential
goal in any cancer treatment is to maintain or improve
the patients’ quality of life (QoL). However, only a few
publications have evaluated the impact of treatment on
the patients’ QoL. SRT does not lead to significant wors-
ening of health related quality of life (HRQoL) in the
first year after treatment. Patients referred for SRT have
substantially worse baseline HRQoL scores than those* Correspondence: j.nuyttens@erasmusmc.nl
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deteriorations in HRQoL subscale scores were not ob-
served after SRT [5]. QoL was evaluated in medically in-
operable patients with NSCLC treated either with SRT
or conventional three-dimensional conformal radiother-
apy. At one year patients treated with SRT had a stable
global QoL and physical functioning (PF)and dyspnea,
while patients treated with 3D-CRT had a decreased PF
approaching clinical significance [6]. In 2009 we pub-
lished the results of the QoL one year after treatment
with SRT, using the European Organization for Research
and Treatment of Cancer (EORTC) quality of life ques-
tionnaire (QLQ) C30 and lung cancer-specific supple-
mentary questionnaire QLQ LC13. QoL was maintained
and the emotional functioning (EF) improved signifi-
cantly. Other function scores and QLQ-C30 and QLQ-
LC13 lung symptoms (such as dyspnea and coughing)
showed no significant changes [7]. To our knowledge,
this is the first study to report the outcome of QoL
5 years after SRT for patients with stage I NSCLC.his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Patients and treatment
Between January 2006 and February 2008, 43 patients who
refused surgery or had an inoperable stage T1-2N0M0
NSCLC entered our prospective phase II trial. The trial
was accepted by the Medical Ethical Committee of the
Erasmus Medical Center (METC Erasmus-MC number:
2005–300) and was in agreement with the Declaration of
Helsinki. Pathological confirmation of malignancy was ob-
tained for all patients. Diagnostic staging included com-
puted tomography (CT) scanning of all patients and
positron emission tomography (PET) scanning for all but
4 patients. Four patients were excluded from analysis due
to a lack of pretreatment assessment (n = 2), progressive
disease 3 weeks after treatment (n = 1), and 1 patient de-
clined to participate after inclusion. Comorbidity was reg-
istered using the Charlson comorbidity index and the
cumulative illness ranking score [8,9]. Patient characteris-
tics are listed in Table 1. One patient included in this ana-
lysis had a T2 tumor at the time of inclusion but a T3
tumor at the time of treatment.
All patients were treated with real-time tumor tracking
using the CyberKnife [10]. The technique has been de-
scribed previously [11]. Treatment consisted of 60 Gy in 3Table 1 Patient and tumor characteristics*
Characteristic No. of patients (% of total)
Medically inoperable 33 (85)
Refused surgery 6 (15)
Charlson Comorbidity Score
0-2 20 (51)
03-apr 13 (33)
<3 6 (15)
Median Cumulative Illness
Ranking (range)
6 (2–16)
Incidence of COPD 22 (56)
Tumor location
Peripheral 33 (85)
Central 6 (15)
T-classification
T1 17 (44)
T2 21 (54)
T3 1 (3)
Histology
Squamous cell carcinoma 14 (36)
Large cell carcinoma 13 (33)
Adenocarcinoma 8 (21)
Other 4 (10)
PTV median (cc) (range) 46 (7–609)
*Median age, 77 years (range, 55–87 years). No: number; PTV: planning
Target Volume.fractions for 30 patients. A risk-adaptive treatment schedule
consisting of 48 to 50 Gy in 5 to 6 fractions was used to
treat 6 patients with central tumors and 1 patient with a
large T2 tumor. Two patients were treated with 45 Gy in 3
fractions by choice of the treating physician. Treatment dose
was prescribed to the 78 to 87% isodose line, covering at
least 95% of the planning target volume (PTV). The max-
imum dose was defined by the 100% isodose line. Treatment
planning was done with the On Target treatment plan-
ning system version 3.4.1 (Accuray Inc., Sunnyvale, CA).
Correction for tissue inhomogeneity was achieved by
using the equivalent path length algorithm. None of the
patients were treated with chemotherapy prior to treat-
ment or in an adjuvant setting.
QoL instruments
QoL assessments were performed before treatment, at
3 weeks, and at 2, 4, 6, 9, 12, 15, 18, 21 and 24 months after
the treatment. After 24 months, the assessments were per-
formed every 6 months until 5 years after the treatment or
death or progressive disease. Patients with evidence of
progressive disease were excluded from further analysis
to prevent bias caused by disease progression or treat-
ment of progressive disease. QoL was evaluated by
means of the European Organization for Research and
Treatment of Cancer (EORTC) core questionnaire, Quality
of Life Questionnaire (QLQ) C30 (version 3.0), and supple-
mentary lung cancer-specific module QLQ-LC13. The
QLQ-C30 is a 30-item questionnaire composed of five
functional scales, three symptom scales, a global health sta-
tus/QoL scale, and six single items. The single items assess
additional symptoms commonly reported by cancer pa-
tients. This questionnaire has proven to be a valid and reli-
able tool when used among a wide range of cancer patient
populations, including lung cancer patients [12]. The lung
cancer module is designed for patients with various disease
stages treated with chemotherapy and/or radiotherapy. It
consists of 13 questions assessing lung cancer-associated
symptoms, treatment-related side effects, and pain medica-
tion. The EORTC QoL and symptom measures were
rescaled to percentages (scores 0 to 100%) through linear
transformation. A high score for the function and QoL
scales represents a high level of functioning/high QoL,
whereas a high symptom score represents a high level of
symptoms. The questionnaires have been translated and
validated for use in a Dutch population.
Follow-up and toxicity scoring
The first clinical examination was performed 3 weeks after
SRT. Clinical follow-up was performed every 3 months,
and a CT scan was performed at 2, 4 and 6 months, and
every 3 months thereafter. After 2 years it was performed
every half year up to 5 years. The patient’s physician
scored the toxicity at each-out patient visit, using common
Table 2 Compliance with quality of life assessments
Time
(months)
Compliance
(%)
Nr. of patients still alive without
progression
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was acute toxicity if it occurred within 4 months and late
toxicity if it occurred thereafter.0.75
(3 weeks)
90 35/39
2 95 35/37
4 95 35/37
6 100 36/36
9 96 27/28
12 95 20/21
15 95 19/20
18 100 20/20
21 95 19/20
24 95 19/20
30 95 18/19
36 78 14/18
42 87 13/15
48 86 12/14
60 100 10/10Statistical analyses
The data in the present study were analyzed with mixed-
effects models to evaluate changes over time in the
mean QoL and symptom scores. Mixed-effects models
are an appropriate tool for the analysis of dependent
data such as data collected in a hierarchical manner, e.g.
when a number of observations are collected over time
on the same patient [13,14]. The advantage of using
mixed-effects models is that they model the evolution of
a longitudinal outcome over time while accounting for
the correlation between repeated measurements in each
patient. Moreover, these models are able to deal with un-
balanced data, that is when the number of observations
per individual is not the same, or when time between re-
peated measurements of each individual varies. Specific-
ally, mixed-effects models consist of the fixed and the
random effects. The fixed effects describe the average
evolution in time of a specific longitudinal outcome (e.g.
one of the five functional scales), while the random ef-
fects describe the evolution in time of each patient. Due
to heterogeneity in the residuals plot, the logarithmic
scale was used for some variables. Missing values due to
non-response of questionnaire were assumed to be miss-
ing at random, which means that the missing value was
assumed to be independent of the unobserved measure-
ment [14,15]. All analyses were performed with the R stat-
istical software (version 2.13.2, 2011. R Development Core
Team 2011, R Foundation for Statistical Computing,
Vienna, Austria). All statistical tests with a P-value of
0.05 or lower were considered significant. Overall sur-
vival was measured from the start of radiotherapy until
death by any cause. Patients still alive at the date of last
contact were censored. Local tumor control was calcu-
lated from the first day of treatment until the diagnosis
of a local recurrence. Patients without a local recurrence
were censored on the last day of contact. In the absence
of biopsy confirmed viable carcinoma, local recurrence
was defined as a 20% increased longest-tumor dimen-
sion on the CT scan compared to the previous CT scan.
In addition, a corresponding avid lesion on the PET scan
was required.Results
Compliance with QoL assessments
QoL was assessed in 39 patients. The mean compliance
over the 5 years was more than 93% (range, 78-100%).
At 5 years 10 patients were still alive without progres-
sion. The details are shown in Table 2.QoL and baseline symptoms
Changes in QLQ-C30 mean global health status (GH) and
function scores (EF, PF and RF) during follow-up are shown
in Figure 1. Changes in QLQ-LC13 mean symptom scores
(dyspnea, coughing and fatigue) are shown in Figure 2.
During the first year, the global health status was near the
baseline value, improved to a score of 4 at 18 months and
then significantly declined (slope: −0.015) to the baseline
value during the next years. The PF score as well as the role
functioning (RF) significantly improved slowly (slope:
0.006 and 0.004, resp.) over the years. Due to the fluctu-
ation of the EF score over the 5 years, the changes over
time were not significant, but the mean EF score at 1 year
was significantly different compared to the pretreatment
score (p = 0.0003). The small rise (slope: 0.004) over time
in the cognitive functioning was also significant (p = 0.004),
but not the social functioning.
The dyspnea score increased during the first 6 months
to a score of 6, then ameliorated after the 1st year. During
the following years, the dyspnea score gradually increased
to a score of 17 at 5 years. This increase (slope: 0.005) over
time was significant (p = 0.006) for the data from the
QLQ-C30 but not for the data from the QLQ-LC13. The
coughing score increased to 4 at 3 weeks after the treat-
ment and slowly decreased during the first 2 years to −11.
After the first 2 years, the score increased to a score of 8
at 5 years (p = 0.57). The fatigue score at one year de-
creased to a score of −10, but raised thereafter to a score
of −0.6 at 5 years. This slow increase (slope: 0.003) over
the 5 years (p = 0.05) was significant.
Figure 1 Change in mean global health and functional scores.
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The overall survival rate was 62% at 2 year and 31% at
5 years. Twenty-seven patients died; 12 patients died from
metastatic disease, and 15 patients died from intercurrent
disease. Causes of intercurrent death are shown in Table 3.
Local tumor control was 97% at 2 years and 93% at 5 years.
Two patients had a local recurrence. The disease free sur-
vival was 69% at 2 years and 52% at 5 years.
Fourteen patients had distant metastases. Of the 14 pa-
tients with distant metastases, 6 patients had mediastinal
lymph nodes. There were no patients with isolated re-
gional recurrence. The median follow-up was 38 months
(range, 4–71 months).Figure 2 Change in mean QLQ-LC13 dyspnea, coughing and fatigue scoreToxicity
Treatment related grade 4 or 5 toxicity didn’t occur.
Twelve patients had no acute side effects at all. The
most common grade 1 and 2 toxicities were respiratory
(dyspnea and coughing). Acute grade 2 toxicity involved
12 patients, of which 6 with dyspnea, 1 with esophageal
pain, 1 with thoracic pain and 4 with coughing. There
were 14 patients with late grade 2 toxicity: dyspnea and
thoracic pain occurred both in 6 patients and chronic
cough in 2. Two patients had acute grade 3 toxicity, 1
with dyspnea and 1 with thoracic pain. Late grade 3 tox-
icity occurred in 4 patients, 2 with dyspnea and 2 with
thoracic pain.s.
Table 3 Causes of death
Cause of death Nr. of patients (Total 27)
Metastatic disease 12
Intercurrent 15
cardiovascular 3
Mortality during surgery 1
Sudden death of unknown cause 3
General deterioration 6
Pulmonal infection 2
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We observed that QoL was maintained 5 years after SRT.
The global health increased during the first 1.5 years but
decreased thereafter to the baseline. The PF and RF sig-
nificantly improved slowly, although the improvements
were small. The EF improved significantly in the first year,
but declined thereafter. Respiratory symptoms (dyspnea
and coughing) did not get worse in the first two years, al-
though it slowly increased in the next years after SRT.
Four other studies have reported health related quality
of life outcomes (HRQoL) after SRT in patients with
early-stage NSCLC [2,5,6,16]. These studies report on
the QoL one to three years after the SBRT. Widder et al.
investigated changes of HRQoL parameters after SRT
(202 patients) and 3-D treatment (27 patients) in two
prospective cohorts of inoperable patients. In all studies,
global QoL and PF were stable after treatment, no statisti-
cally or clinically significant worsening of any of the
HRQoL functioning or symptom scores at any follow-up
time point was observed in our and other mentioned stud-
ies [5,6,16]. Most noticeable difference is that our study
showed a statistically significant improvement of the EF at
1 year. Mathieu et al. did report a trend in QLQ-C30 emo-
tional score improvement of 14 at 36 months [16].
A prospective study with patients diagnosed with early
stage lung cancer undergoing 3D-CRT showed a gradual
and significant increase in dyspnea, fatigue, and appetite
loss, together with a significant deterioration of RF com-
pared to the base line measurement. The global QoL did
not deteriorate, EF did not improve. Their hypothesis for
worsening of dyspnea and fatigue was because of pre-
existing, slowly progressive chronic obstructive pulmon-
ary disease (COPD) and radiation-induced pulmonary
changes [17].
Langendijk et al. investigated the effect of respiratory
symptoms on QoL in patients with stage I-III lung cancer
during the first 2 years after the treatment. At the base
line, dyspnea was the most important and significant re-
spiratory symptom affecting all EORTC scales, with the
exception of EF [18].
In comparison with surgery, the HRQoL after stereotac-
tic radiotherapy compared to HRQoL after the surgery isat 3 or 6 months after the treatment in general better.
Poghosyan et al. reviewed 19 out of 337 studies and con-
cluded that participants had worse physical function at 6-
months after surgery and had decreased physical function
up to 2-years after surgery, compared to the pre-surgical
status. Pain, fatigue, dyspnea and coughing were the most
prevalent symptoms. Increased levels of dyspnea and fa-
tigue persisted for at least 2-years after surgery. Kenny at
al. who studied the HRQoL in 173 patients with stage I
and II NSCLC reported that surgery substantially reduced
HRQoL across all dimensions except emotional function-
ing. HRQoL improved in the 2 years after surgery for pa-
tients without disease recurrence, although approximately
half continued to experience symptoms and functional
limitations.
There is not much known about the quality of life
more than 2 years after the treatment in patients with
early stage lung cancer. It is generally known that pa-
tients with COPD have a decline of their long function
over time. This is mainly based on the study of Fletcher
and Peto [19]. More than 35 years ago, they did report
on the natural history of tobacco smoke–related chronic
airflow obstruction. Fletcher and Peto measured the
forced expiratory volume in 1 second (FEV1) every
6 months for an 8-year follow-up period in a cohort of
792 working men and concluded that a lower FEV1 de-
clined greater for similar intervals of time in COPD pa-
tients who smoked. However recent research found that
patients with COPD GOLD stage I had a decline of
about 40 ml/year, patients with COPD GOLD stage II a
decline of 47–79 ml/year, patients with COPD GOLD
stage III, a decline of 56–59 ml/year, and patients with
COPD GOLD stage IV a decline of <35 ml/year [20,21].
Many of our patients had COPD. The dyspnea score in-
creased during the first 6 months to a score of 6, then
ameliorated after the 1st year (score −3). During the fol-
lowing years, the dyspnea score gradually increased to a
score of 17 at 5 years. So the increase of the dyspnea
score after the 1st year can be related to decline of the
lung function over time or due to the radiotherapy.
Probably it is caused by both. Several studies did report
on the QoL in patients with COPD. Carrasco Garrido
et al. did report on the HRQoL in 10711 patients and
concluded that patients with stable COPD stages 2–4
did show a reduction of their HRQoL, even in mild
stages of the disease. The factors determining the
HRQoL include sex, FEV1, use of oxygen therapy, and
number of visits to emergency rooms and hospital ad-
missions [22]. Bridevaux et al. studied 519 patients with
COPD GOLD stage I and concluded also that these pa-
tients have a lower QoL than the 3627 asymptomatic
subjects with normal lung function. The slow decline of
the global health (GH) score over the last 3 years is
maybe caused by the decrease of the lung function and
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well as the RF ameliorated slowly over the years. How-
ever, the impact in COPD in patients with lung cancer is
not completely clear [23]. Mohan et al. studied 160 pa-
tients with COPD and stage III and IV lung cancer and
concluded that no significant differences were found in
clinical profile, Karnofsky performance status, or QoL
scores between patients with and without COPD [24].
On the other hand, Gore et al. compared the QoL in
end-stage COPD patient with NSCLC patients and con-
cluded that the end-stage COPD patients experienced a
poor HRQoL comparable to or worse than that of ad-
vanced NSCLC patients [25].
The actuarial overall survival of our study was 62% at
2 years and 31% at 5 years. The actuarial local tumor con-
trol was 97% at 2 years and 93% at 5 years. This is in agree-
ment with other studies: Widder et al. reported estimates
at two years for 3D-CRT versus SRT of 48% versus 72% for
overall survival (OS),and 78% versus 95% for local control
(LC), respectively [6]. In the patient-report of Lagerwaard
et al. HRQoL data were collected prospectively in 382 con-
secutive patients treated with SRT. The median survival
was 40 months, with a 2-year OS of 66% [5].
In our study the overall compliance was more than
93%, so the missing data of QoL assessments is minimal.
Though, the major limitation of this study was the small
number of patients with increasing follow-up time.
Therefore the study has not enough power and should
be seen as descriptive, as this is the first report about
QoL during 5-years. More research will be needed, espe-
cially a bigger number of patients for more data.Conclusions
During the 5 years after treatment with stereotactic
radiotherapy for stage I NSCLC, the level of QoL was
maintained: There was a slow decline of the Global
Health status over the 5 years (p < 0.0001). The physical
functioning score as well as the role function score did
ameliorated slowly over the years and this was also sig-
nificant (p < 0.0001). The emotional functioning im-
proved significantly at 1 year compared to the base line.
Two years after the treatment, the dyspnea slowly
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